Technical Analysis for PTN - Palatin Technologies, Inc.

Grade Last Price % Change Price Change
grade D 0.385 6.94% 0.03
PTN closed up 6.94 percent on Thursday, June 22, 2017, on 62 percent of normal volume. It ran into resistance at its 50 day moving average.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical PTN trend table...

Date Alert Name Type % Chg
Jun 22 50 DMA Resistance Bearish 0.00%
Jun 22 Bollinger Band Squeeze Range Contraction 0.00%
Jun 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jun 21 Bollinger Band Squeeze Range Contraction 6.94%
Jun 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.94%

Older signals for PTN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Get Started for Free!
Basic chart:

Profile
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Is PTN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 16 Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT
May 16 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
May 11 Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
Mar 31 Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
Mar 20 Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Mar 9 Palatin Technologies To Present At The 29th Annual ROTH Conference
Feb 27 AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
Feb 22 Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
Feb 16 AMAG Pharmaceuticals Inks $60M Drug Deal
Feb 9 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
See more PTN news...
Indicators
Indicator Value
52 Week High 0.9
52 Week Low 0.2851
Average Volume 2,029,826
200-Day Moving Average 0.4587
50-Day Moving Average 0.3894
20-Day Moving Average 0.3611
10-Day Moving Average 0.3598
Average True Range 0.0229
ADX 10.14
+DI 24.24
-DI: 21.21
Chandelier Exit (Long, 3 ATRs) 0.3313
Chandelier Exit (Short, 3 ATRs) 0.4087
Upper Bollinger Band 0.3824
Lower Bollinger Band 0.3398
Percent B (%b) 1.06
Bandwidth 0.117973
MACD Line -0.0063
MACD Signal Line -0.0098
MACD Histogram 0.0035